Perimenopausal Melatonin Deficiency Syndrome in a System of Personalized Management for the Quality of Life of Women with Climacteric Syndrome

Усольцева, Е. Н.; Soloviev, A. G.; Mamontova, A. G.

doi:10.1134/s2079057020010154

Cited by 4 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, perimenopausal women often suffer from sleep disorders such as insomnia and abnormal rhythms, which can persist until late menopause and lead to concomitant symptoms such as vascular tension symptoms, anxiety, depression, and cognitive decline, which in turn have a serious negative impact on patients' quality of life [7][8][9]. Hormone therapy is one of the common ways of clinical treatment of menopausal syndrome [10]. Data show that hormone therapy can not only improve women's estrogen levels, reduce physical, and mental disorders but also help reduce the incidence of cardiovascular diseases [11].…”

Section: Introductionmentioning

confidence: 99%

A Clinical Study of the Effect of Estradiol Valerate on Sleep Disorders, Negative Emotions, and Quality of Life in Perimenopausal Women

Zhang¹,

Shao²,

Ye³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

In this prospective study, we randomly divided 100 patients with perimenopausal syndrome equally into the control group (n = 50) receiving conventional treatment and the study group (n = 50) receiving estradiol valerate. The indicators observed were endometrial thickness, uterine volume, and the levels of LH (luteinizing hormone), FSH (follicle-stimulating hormone), and E2 (estradiol) of the patients before and after treatment. The Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety/Depression Scale (HAMA/HAMD), Kupperman symptom score, and menopause-specific quality of life (MENQOL) were also applied to assess the sleep quality, negative emotions, severity of the condition, and quality of life of all patients, respectively. Our findings were that estradiol valerate is beneficial in improving serum sex hormone levels, sleep disturbances, negative mood, and quality of life in patients with perimenopausal syndrome and that its safety profile is high enough to warrant clinical promotion.

show abstract

Section: Introductionmentioning

confidence: 99%

A Clinical Study of the Effect of Estradiol Valerate on Sleep Disorders, Negative Emotions, and Quality of Life in Perimenopausal Women

Zhang¹,

Shao²,

Ye³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…It is known that the level of MT is unstable during menstrual cycle and decreases at menopause [5,6].Nowadays a new term is proposed -SPDM, which is formed because of MT synthesis decrease in perimenopausal women [1]. This study shows that CC is formed in women, both at menopausal transition and at menopause affected by SPDM.…”

Section: Attractiveness (Att)mentioning

confidence: 78%

“…Nowadays, a new concept -perimenopausal melatonin deficiency syndrome (SPDM) is suggested. SPDM is a complex of symptoms, which is often formed amid decrease of the melatonin synthesis and clinically characterized by the prevalence of complaints of sleep disorders, bodily pain, depression, anxiety/fears and somatic symptoms (fatigue, dizziness, nausea; back and limb pain; tingling in the hands/feet) [1]. SPDM is a donosological state and it is a predecessor of a clinical form of the pathological climacteria developmentclimacteric syndrome (CC).…”

Section: Introductionmentioning

confidence: 99%

Syndrome of perimenopausal melatonin deficiency is a new marker of women reproductive system aging

2020

View full text Add to dashboard Cite

The aim of our study was to determine a complex of risk factors of the perimenopausal melatonin deficiency syndrome (SPDM) in postmenopausal women and women during menopausal transition suffering from climacteric syndrome. The study involved 278 women. They were divided into two groups: I group included 246 menopausal women and II group included 32 women during the menopausal transition. The Medical History was collected, the menopausal index, and anthropometric measures were determined. The study was conducted with a help of the test questionnaire for melatonin deficiency (TQMD), the women’s health questionnaire (WHQ), and detection of the level of 6- sulfatoxymelatonin (6-SOMT) in urine. According to the obtained data, risk factors of SPDM in women during the menopausal transition are the chronological age increment, overweight, and the reduction of the estradiol level. The leading risk factors of SPDM in postmenopausal women are the chronological age increment, overweight with visceral type of obesity and changes in the hormonal profile. Thus, SPDM is a new clinical and laboratory marker of aging of the female reproductive system, an important screening tool for detecting the development of CC in women during the menopausal transition and menopausal women.

show abstract

“…Sleep problems increase with age and are more common in women than men and increased in women over 45 years of age [2]. Studies of perimenopausal sleep disorders have revealed that difficulty falling sleep and frequent nighttime awakenings are due to insufficient melatonin production [3,4]. In vertebrates, melatonin is centrally synthesized by the pineal gland as well as being produced in peripheral tissues and acts as an autocrine and paracrine signal [5].…”

Section: Introductionmentioning

confidence: 99%

Melatonin Alleviates Perimenopausal Sleep Disorders by Regulating the Expression of MTNR1A and Hormone Level: A Retrospective Study

Chen¹,

Zhang²,

Zhang³

2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: Sleep disorder, frequently observed among perimenopausal women, decreases quality of life. Melatonin is reported to ameliorate circadian imbalances and thus can be employed as a treatment for perimenopausal sleep disorder patients. We attempted to clarify whether and how melatonin affects perimenopausal sleep disorders. Methods: Study patients consisted of 120 perimenopausal women divided into 3 groups: (i) perimenopausal women without sleep disorder (n = 60); (ii) those with sleep disorder but without melatonin treatment (n = 30); and (iii) those with sleep disorder with melatonin treatment (n = 30). During the period March 2019 to December 2019, the following data was collected and analyzed: Pittsburgh Sleep Quality index (PSQI) score, sex hormones, melatonin, melatonin 1A receptor (MTNR1A), protein kinase A (PKA), extracellular signal-regulated kinase 1/2 (ERK1/2), phosphorylation-PKA (p-PKA), and p-ERK1/2 levels. We compared these data between the groups. Results: Melatonin administration showed the following in female patients with postmenopausal sleep disorder: (1) significantly decreased the PSQI scores, (2) up-regulated melatonin levels and MTNR1A protein expression, (3) promoted the phosphorylation pathway of the PKA-ERK1/2 pathway in peripheral blood, and (4) significantly improved follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. Melatonin administration had no significant effect on progesterone (P), testosterone (T) or prolactin (PRL). Conclusions: Melatonin therapy alleviated perimenopausal sleep disorders. Up-regulation of MTNR1A expression and improvement of the hormone balance were also observed, which may the reason for the observed sleep-disorder-amelioration. Melatonin has the potential to be a useful option for perimenopausal sleep disorders.

show abstract

Perimenopausal Melatonin Deficiency Syndrome in a System of Personalized Management for the Quality of Life of Women with Climacteric Syndrome

Cited by 4 publications

References 2 publications

A Clinical Study of the Effect of Estradiol Valerate on Sleep Disorders, Negative Emotions, and Quality of Life in Perimenopausal Women

A Clinical Study of the Effect of Estradiol Valerate on Sleep Disorders, Negative Emotions, and Quality of Life in Perimenopausal Women

Syndrome of perimenopausal melatonin deficiency is a new marker of women reproductive system aging

Melatonin Alleviates Perimenopausal Sleep Disorders by Regulating the Expression of MTNR1A and Hormone Level: A Retrospective Study

Contact Info

Product

Resources

About